Drug Search Results
More Filters [+]

Resatorvid

Alternative Names: resatorvid, tak-242, tak 242, tak242
Latest Update: 2024-06-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TLR4 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Resatorvid

Countries in Clinic: Germany, Portugal, Spain

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Acute Kidney Injury|Kidney Diseases|Liver Cirrhosis|Liver Failure, Acute|Respiratory Insufficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

G-TAK-ES-01

P2

Unknown Status

Acute Kidney Injury|Liver Failure, Acute|Kidney Diseases|Respiratory Insufficiency|Liver Cirrhosis

2025-01-31

Recent News Events